Simultaneous Evaluation of Diagnostic Assays for Pharyngeal and Rectal Neisseria gonorrhoeae and Chlamydia trachomatis Using a Master Protocol

Sarah B Doernberg, Lauren Komarow, Thuy Tien T Tran, Zoe Sund, Mark W Pandori, David Jensen, Ephraim L Tsalik, Carolyn D Deal, Henry F Chambers, Vance G Fowler, Scott R Evans, Robin Patel, Jeffrey D Klausner, Sarah B Doernberg, Lauren Komarow, Thuy Tien T Tran, Zoe Sund, Mark W Pandori, David Jensen, Ephraim L Tsalik, Carolyn D Deal, Henry F Chambers, Vance G Fowler, Scott R Evans, Robin Patel, Jeffrey D Klausner

Abstract

Background: Pharyngeal and rectal Neisseria gonorrhoeae and Chlamydia trachomatis play important roles in infection and antibacterial resistance transmission, but no US Food and Drug Administration (FDA)-cleared assays for detection at these sites existed prior to this study. The objective was to estimate performance of assays to detect those infections in pharyngeal and rectal specimens to support regulatory submission.

Methods: We performed a cross-sectional, single-visit study of adults seeking sexually transmitted infection testing at 9 clinics in 7 states. We collected pharyngeal and rectal swabs from participants. The primary outcome was positive and negative percent agreement for detection of N. gonorrhoeae and C. trachomatis for 3 investigational assays compared to a composite reference. Secondary outcomes included positivity as well as positive and negative predictive values and likelihood ratios. Subgroup analyses included outcomes by symptom status and sex.

Results: A total of 2598 participants (79% male) underwent testing. We observed N. gonorrhoeae positivity of 8.1% in the pharynx and 7.9% in the rectum and C. trachomatis positivity of 2.0% in the pharynx and 8.7% in the rectum. Positive percent agreement ranged from 84.8% to 96.5% for different anatomic site infection combinations, whereas negative percent agreement was 98.8% to 99.6%.

Conclusions: This study utilized a Master Protocol to generate diagnostic performance data for multiple assays from different manufacturers in a single study population, which ultimately supported first-in-class FDA clearance for extragenital assays. We observed very good positive percent agreement when compared to a composite reference method for the detection of both pharyngeal and rectal N. gonorrhoeae and C. trachomatis.

Clinical trials registration: NCT02870101.

Keywords: Chlamydia trachomatis; Neisseria gonorrhoeae; nucleic acid amplification techniques; diagnostic techniques and procedures; sexually transmitted infections.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Schematic of the Master Protocol concept from the prototype perspective of evaluation of diagnostic performance of assay 1. The results from assays 2 and 3 determine the anatomic site infected status for assay 1. Tiebreaker tests are performed only if indicated. Evaluation of assay 2 and 3 would proceed utilizing a similar approach. Individuals depicted in black and yellow represent participants without and with infection, respectively.
Figure 2.
Figure 2.
Standards for Reporting of Diagnostic Accuracy Studies diagram of participant flow. Abbreviation: ASIS, anatomic site infected status.
Figure 3.
Figure 3.
A, Positive predictive value (PPV) as a function of Neisseria gonorrhoeae prevalence. B, Negative predictive value (NPV) as a function of N. gonorrhoeae prevalence. C, PPV as a function of Chlamydia trachomatis prevalence. D, NPV as a function of C. trachomatis prevalence. All blue bands reflect 95% confidence intervals.

References

    1. Klausner JD. The NAAT is out of the bag. Clin Infect Dis 2004; 38:820–1.
    1. Workowski KA, Bolan GA; Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1–137.
    1. Ito M, Deguchi T, Mizutani KS, et al. . Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in central Japan. Antimicrob Agents Chemother 2005; 49:137–43.
    1. Lewis DA. Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains? Sex Transm Infect 2015; 91:234–7.
    1. Whittles LK, Didelot X, Grad YH, White PJ. Testing for gonorrhoea should routinely include the pharynx. Lancet Infect Dis 2018; 18:716–7.
    1. Jones RB, Rabinovitch RA, Katz BP, et al. . Chlamydia trachomatis in the pharynx and rectum of heterosexual patients at risk for genital infection. Ann Intern Med 1985; 102:757–62.
    1. Bernstein KT, Stephens SC, Barry PM, et al. . Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men. Clin Infect Dis 2009; 49:1793–7.
    1. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr 2010; 53:537–43.
    1. Weinstock H, Workowski KA. Pharyngeal gonorrhea: an important reservoir of infection? Clin Infect Dis 2009; 49:1798–800.
    1. Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014. MMWR Recomm Rep 2014; 63: 1–19.
    1. Renault CA, Hall C Kent CK, Klausner JD.. Use of NAATs for STD diagnosis of GC and CT in non-FDA -cleared anatomic specimens. MLO Med Lab Obs 2006; 38: 10, 12–6, 21–2; quiz 24, 27.
    1. Hadgu A. The discrepancy in discrepant analysis. Lancet 1996; 348:592–3.
    1. Hawkins DM, Garrett JA, Stephenson B. Some issues in resolution of diagnostic tests using an imperfect gold standard. Stat Med 2001; 20:1987–2001.
    1. Miller WC. Bias in discrepant analysis: when two wrongs don’t make a right. J Clin Epidemiol 1998; 51:219–31.
    1. Martin DH, Nsuami M, Schachter J, et al. . Use of multiple nucleic acid amplification tests to define the infected-patient “gold standard” in clinical trials of new diagnostic tests for Chlamydia trachomatis infections. J Clin Microbiol 2004; 42:4749–58.
    1. US Food and Drug Administration. Statistical guidance on reporting results from studies evaluating diagnostic tests—guidance for industry and FDA staff. Available at: . Accessed 17 April 2018.
    1. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017; 377:62–70.
    1. Patel R, Tsalik EL, Petzold E, Fowler VG Jr, Klausner JD, Evans S; Antibacterial Resistance Leadership Group MASTERMIND: bringing microbial diagnostics to the clinic. Clin Infect Dis 2017; 64:355–60.
    1. Abbott Laboratories. Abbott RealTime CT/NG package insert. Abbott Park, IL: Abbott, 2010.
    1. Cepheid. Xpert CT/NG assay package insert. Rev B. ed. Sunnyvale, CA: Cepheid, 2013.
    1. Hologic. APTIMA Neisseria gonorrhoeae assay. Rev A73 ed. Marlborough, MA: Hologic, 2011.
    1. Hologic. APTIMA Chlamydia trachomatis assay. Rev D ed. Marlborough, MA: Hologic, 2012.
    1. Hologic. Aptima Combo 2 assay package insert. Rev D ed. Marlborough, MA: Hologic, 2012.
    1. US Food and Drug Administration, Center for Devices and Radiological Health. Draft guidance for industry and Food and Drug Administration staff establishing the performance characteristics of in vitro diagnostic devices for Chlamydia trachomatis and/or Neisseria gonorrhoea: screening and diagnostic testing. FDA, 2011.
    1. Bonett DG, Price RM. Confidence intervals for a ratio of binomial proportions based on paired data. Stat Med 2006; 25:3039–47.
    1. Altman D, Machin D, Bryant T, Gardner M.. Statistics with confidence: confidence intervals and statistical guidelines. 2nd ed.Bristol, UK: BMJ Books, 2000.
    1. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17:857–72.
    1. Ota KV, Tamari IE, Smieja M, et al. . Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in pharyngeal and rectal specimens using the BD Probetec ET system, the Gen-Probe Aptima Combo 2 assay and culture. Sex Transm Infect 2009; 85:182–6.
    1. Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008; 35:637–42.
    1. Bachmann LH, Johnson RE, Cheng H, et al. . Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 2010; 48:1827–32.
    1. Cosentino LA, Danby CS, Rabe LK, et al. . Use of nucleic acid amplification testing for diagnosis of extragenital sexually transmitted infections. J Clin Microbiol 2017; 55:2801–7.
    1. Geelen T, Rossen J, Antoine MB, et al. . Performance of Cobas 4800 and m2000 real-time assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and self-collected vaginal specimen. Diagn Microbiol Infect Dis 2013; 77:101–5.
    1. Moncada J, Schachter J, Liska S, Shayevich C, Klausner JD. Evaluation of self-collected glans and rectal swabs from men who have sex with men for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of nucleic acid amplification tests. J Clin Microbiol 2009; 47:1657–62.
    1. Perry MD, Jones RN, Corden SA. Is confirmatory testing of Roche Cobas 4800 CT/NG test Neisseria gonorrhoeae positive samples required? Comparison of the Roche Cobas 4800 CT/NG test with an opa/pap duplex assay for the detection of N gonorrhoeae. Sex Transm Infect 2014; 90:303–8.
    1. Bachmann LH, Johnson RE, Cheng H, Markowitz LE, Papp JR, Hook EW 3rd. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae oropharyngeal infections. J Clin Microbiol 2009; 47:902–7.
    1. Mercaldo ND, Lau KF, Zhou XH. Confidence intervals for predictive values with an emphasis to case-control studies. Stat Med 2007; 26:2170–83.
    1. US Food and Drug Administration. FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea [FDA news release] Available at: . Accessed 21 June 2019.
    1. Cornelisse VJ, Chow EP, Huffam S, et al. . Increased detection of pharyngeal and rectal gonorrhea in men who have sex with men after transition from culture to nucleic acid amplification testing. Sex Transm Dis 2017; 44:114–7.
    1. Centers for Disease Control and Prevention. Press release: new CDC analysis shows steep and sustained increases in STDs in recent years. Available at: . Accessed 31 August 2018.
    1. Allan-Blitz LT, Humphries RM, Hemarajata P, et al. . Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of Neisseria gonorrhoeae in a large health system. Clin Infect Dis 2017; 64:1268–70.
    1. Harryman L, Scofield S, Macleod J, et al. . Comparative performance of culture using swabs transported in Amies medium and the Aptima Combo 2 nucleic acid amplification test in detection of Neisseria gonorrhoeae from genital and extra-genital sites: a retrospective study. Sex Transm Infect 2012; 88:27–31.
    1. Trebach JD, Chaulk CP, Page KR, Tuddenham S, Ghanem KG. Neisseria gonorrhoeae and Chlamydia trachomatis among women reporting extragenital exposures. Sex Transm Dis 2015; 42:233–9.
    1. Chan PA, Robinette A, Montgomery M, et al. . Extragenital infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol 2016; 2016:5758387.
    1. Dewart CM, Bernstein KT, DeGroote NP, Romaguera R, Turner AN. Prevalence of rectal chlamydial and gonococcal infections: a systematic review. Sex Transm Dis 2018; 45:287–93.
    1. Patton ME, Kidd S, Llata E, et al.Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men—STD Surveillance Network, United States, 2010–2012. Clin Infect Dis 2014; 58:1564–70.
    1. Andersson N, Boman J, Nylander E. Rectal chlamydia—should screening be recommended in women? Int J STD AIDS 2017; 28:476–9.
    1. van Liere GAFS, Dukers-Muijrers NHTM, Levels L, Hoebe CJPA. High proportion of anorectal Chlamydia trachomatis and Neisseria gonorrhoeae after routine universal urogenital and anorectal screening in women visiting the sexually transmitted infection clinic. Clin Infect Dis 2017; 64:1705–10.
    1. Barry PM, Kent CK, Philip SS, Klausner JD. Results of a program to test women for rectal chlamydia and gonorrhea. Obstet Gynecol 2010; 115:753–9.
    1. Hess AS, Shardell M, Johnson JK, et al. . Methods and recommendations for evaluating and reporting a new diagnostic test. Eur J Clin Microbiol Infect Dis 2012; 31:2111–6.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit